Metric choice in Checkpoint Inhibitor Dose Predictions

Checkpoint inhibitors prevent the interaction between membrane-bound ligands and membrane receptors within the immune synapse. Applied BioMath Assess enables modeling of the immune synapse with the membrane-ligand biotherapeutic models. Within these models, target engagement is not always a good predictor of inhibition of ligand–receptor activity. This case study highlights the capabilities of Assess for early feasibility assessment of checkpoint inhibitors and other membrane-ligand-targeted drugs.